Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004070 · ClinicalTrials.gov registry record · Phase 1
Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT00004070 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 7 participants.
The verdict
NCT00004070, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
Participant with squamous cell cancer of head and neck are invited to participate in this study. In this study the investigators will be Inserting the gene for interleukin-12 into a person's cancer cells with the anticipation to make the body build an immune response to kill more tumor cells.
Interventions
- BIOLOGICAL IL-12
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 1999-07 |
| Est. Completion | 2000-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004070
The ClinicalTrials.gov registry entry for NCT00004070 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IL-12 is the first listed.
NCT00004070 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004070 about?
NCT00004070 is a clinical study titled "Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer". Participant with squamous cell cancer of head and neck are invited to participate in this study. In this study the investigators will be Inserting the gene for interleukin-12 into a person's cancer cells with the anticipation to make the body build an immune response to kill more tumor cells.
What is the current status of trial NCT00004070?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 1999-07. Estimated completion is 2000-12.
What interventions are being tested in trial NCT00004070?
The interventions under investigation include: IL-12 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00004070?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.